When was Oligomerix founded?

Oligomerix was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is Oligomerix located?

Oligomerix is headquartered in New York City, United States.

Who is the current CEO of Oligomerix?

James Moe of Oligomerix. They have also founded 1 company.

How many employees does Oligomerix have?

As of Jun 30, 2026, the latest employee count at Oligomerix is 12.

Is Oligomerix a funded company?

Oligomerix is a funded company, having raised a total of $7.9M across 27 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 01, 2007.

When was the latest funding round of Oligomerix?

Oligomerix's latest funding was a $***** Grant (prize money) round on Jun 17, 2026, with participation from 1 investor.

Where does Oligomerix rank among its competitors?

Oligomerix ranks 47th amongst 457 active competitors, of which 161 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Oligomerix, which secured $1.9M in Jun, 2026.

Who are the top competitors of Oligomerix?

Oligomerix's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Oligomerix secured the most recent funding round in June, 2026.

Oligomerix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases . It has developed two approaches for small molecule drug discovery tau oligomer inhibitor program and tau protease inhibitor program. Its drugs target neurotoxic tau oligomers that impair learning and memory and that cause spread of Alzheimer’s and related neurodegenerative diseases in the brain.

Key Metrics

Founded Year

2006

Location

New York City, United States

Stage

Series B

Total Funding

$7.9M in 27 rounds

Latest Funding Round

Grant (prize money), Jun 17, 2026, $*****

Investors

Counterview Capital & 5 more

Ranked

47^th among 457 active competitors

Employee Count

12 as on Jun 30, 2026

Similar Companies

Denali Therapeutics & 567 more

View Oligomerix's full profile

Oligomerix has raised a total funding of $7.9M over 27 rounds. Its first funding round was on May 01, 2007. Its latest funding round was a Grant (prize money) round on Jun 17, 2026 for $*****. 1 investor participated in its latest round. Oligomerix has 6 institutional investors.

Here is the list of recent funding rounds of Oligomerix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2026	5355087	Grant (prize money)	6984631	6621055	1002488	4102714
Sep 17, 2025	8374161	Grant (prize money)	8852008	2109394	2382527	HHS
Aug 18, 2025	5075401	Grant (prize money)	3776280	5217185	5194368	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Oligomerix's funding rounds and investors

The founders of Oligomerix are James Moe and Eliot Davidowitz. James Moe is the CEO of Oligomerix.

Here are the details of Oligomerix's key team members:

James Moe: Co-Founder & CEO & President of Oligomerix.
Contact Info: 1 email address
Eliot Davidowitz: Co-Founder of Oligomerix.
Contact Info: 1 email address

View details of Oligomerix's Founder profiles and Board Members

Oligomerix's employee count trend

Oligomerix has 12 employees as of Jun 26. Here is Oligomerix's employee count trend over the years:

Uncover Oligomerix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oligomerix include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Oligomerix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
47th	Oligomerix 2006, New York City (United States), Series B	Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases	$7.9M	Counterview Capital, Wheatley Partners & 4 others	54/100